Unresectable mass-forming intrahepatic cholangiocarcinoma
Conditions
Interventions
Observation group (TACE treatment with small diameter Drug-Eluting Beads(70-150µm) ):None
Sponsors
Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1)mass-forming intrahepatic cholangiocarcinoma was clinical diagnosed; 2)Patients who were evaluated by 2 associate senior hepatobiliary surgeons or above for patients who could not be surgically resected or who failed first-line systemic chemotherap; 3)ECOG PS 0-1; 4)Good liver function(Child grade A\B); 5)Life expectancy = 3 months; 6)Aged 18-75 years; 7)Signed informed consent;
Exclusion criteria
Exclusion criteria: 1) Severe active infection greater than grade 2 (except hepatitis B or C infection); 2) With malignant tumors of other organs; 3) Severe heart, lung and kidney diseases; 4) Pregnant or lactating women; 5) Those who have severe neurological lesions and can not clearly describe the response of treatment; 6) Patients with severe atherosclerosis; 7) AIDS patients; 8) Patients with severe gastrointestinal bleeding within 4 weeks; 9) Severe thrombosis or emboli within 6 months; 10) Is participating in other clinical trials or is preparing to participate in other clinical trials; 11) Patients who are considered inappropriate by the investigator (poor compliance and cannot be followed-up)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median Survival Time;Time To Progress;Survival Rate of 6.12.18 month;Tumor responses; | — |
Countries
China
Contacts
Public ContactLiu Ying
Beijing Tsinghua Changgung Hospital
Outcome results
None listed